Table 2.
Non-exclusive ever use of hypolipidemic medications, University of California San Francisco case-control study of pancreatic cancer.
| Hypolipidemic Medication1 | Cases (n=536) | Controls (n=869) |
|---|---|---|
|
| ||
| n (%) | n (%) | |
| Never | 354 (66.0) | 548 (63.1) |
| Ever | 181 (34.0) | 320 (36.9) |
|
| ||
| Any Statin | 175 (32.6) | 310 (35.7) |
| Atorvastatin | 97 (18.1) | 213 (24.5) |
| Fluvastatin | 1 (0.2) | 2 (0.2) |
| Lovastatin | 31 (5.8) | 46 (5.3) |
| Pravastatin | 7 (1.3) | 42 (4.8) |
| Rosuvastatin | 9 (1.7) | 11 (1.3) |
| Simvastatin | 70 (13.1) | 108 (12.4) |
| Bile Acid Sequestrants | 3 (0.6) | 3 (0.3) |
| Cholesterol Absorption Inhibitors | 20 (3.7) | 26 (3.0) |
| Fibrates | 8 (1.5) | 11 (1.3) |
| Nicotinic Acid | 3 (0.6) | 19 (2.2) |
|
| ||
|
No. of Different Statin Medications
| ||
| 0 | 360 (67.3) | 558 (64.3) |
| 1 | 144 (26.9) | 225 (25.9) |
| 2 | 26 (4.9) | 62 (7.1) |
| 3–4 | 5 (0.9) | 23 (2.7) |
1
Unknown: N=2.